Blueberries Medical (BBM.CN CNQ) down 25.00% to C$0.015 on 06 Feb 2026: valuation risk

BBM.CN stock slid 25.00% to C$0.015 on 06 Feb 2026 during Canadian market hours, marking it among the session’s top losers on the CNQ exchange. Volume was light at 2,500 shares versus a 30‑day average of 5,474, and market cap tightened to C$7,426,351.00. The move follows weak trading liquidity, a low float and continued negative EPS of -0.01, and it amplified valuation questions for Blueberries Medical Corp. in Canada.

BBM.CN stock: price action and immediate market facts

Blueberries Medical Corp. (BBM.CN) traded at C$0.015 after opening at C$0.015, with a previous close of C$0.02 and a day range of C$0.015–C$0.015. The one‑day change of -25.00% is the largest intraday drop in recent sessions and follows a year high of C$0.025 and a year low of C$0.005. The stock’s relative volume was low at 0.40x, underlining weak liquidity on the CNQ market in Canada.

BBM.CN stock: drivers behind the selloff

Two structural drivers explain the decline: thin trading and negative fundamentals. Shares outstanding are 495,090,087, but average daily volume is only 5,474, so small orders cause high percentage swings. Second, trailing EPS is -0.01 and the reported PE is negative at -1.50, signaling ongoing losses and investor caution.

BBM.CN stock: financial snapshot and valuation

Blueberries Medical shows a market cap of C$7,426,351.00, revenue per share TTM 0.00084, and book value per share 0.00155, producing stretched valuation ratios such as price to sales 17.94 and price to book 9.68. The company has a current ratio of 2.10, low debt to equity 0.01, and operating cash flow per share -0.00264, indicating liquidity buffers but negative cash generation.

BBM.CN stock: Meyka AI grade and analyst signals

Meyka AI rates BBM.CN with a score of 67.57 out of 100 (Grade B, HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Independent company data shows a separate company rating of C (Sell) dated 05 Feb 2026, reflecting weak profitability metrics such as ROE and ROA. These mixed signals suggest a cautious stance from model-driven and fundamental angles.

BBM.CN stock: technicals, momentum and liquidity metrics

Technical indicators show an RSI of 38.02 and CCI -144.24, consistent with oversold short-term momentum. Bollinger Bands sit at 0.01/0.02, and the MACD reads near zero, indicating low trading inertia. On‑balance volume is negative and MFI is 24.01, confirming selling pressure. With average volume at 5,474 and current volume 2,500, liquidity risk is elevated for traders.

BBM.CN stock: forecasts, targets and scenario planning

Meyka AI’s forecast model projects a monthly target of C$0.01 and a yearly target of C$0.00733, versus the current price of C$0.015, implying potential downside of -33.33% on a one‑month view and -51.14% on a one‑year view. Short‑term technical support sits near the year low C$0.005 and resistance near the year high C$0.025. These levels form a practical price target range for risk‑managed trades, while forecasts remain model‑based and not guarantees.

Final Thoughts

BBM.CN stock’s 25.00% drop to C$0.015 on 06 Feb 2026 highlights the twin risks of thin liquidity and weak fundamentals for Blueberries Medical Corp. on the CNQ exchange in Canada. Financial ratios — price/sales 17.94 and price/book 9.68 — look stretched given negative EPS -0.01 and negative operating cash flow per share -0.00264. Meyka AI rates BBM.CN 67.57/100 (Grade B, HOLD) while an independent company rating lists C (Sell), creating mixed signals that favor caution. Meyka AI’s forecast model projects C$0.01 monthly and C$0.00733 yearly, implying downside versus today’s price; forecasts are model projections and not guarantees. Traders seeking exposure should weigh volatility, the stock’s low average volume of 5,474, and potential support at C$0.005 against any recovery catalyst. For continued monitoring see company filings and the latest market data on Blueberries Medical website and trading comparisons on Investing.com. Meyka AI provides this as AI-powered market analysis to support investor research, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.